TFFP · Tff Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $193.4K | $650.2K | $203.3K | - | $234.8K | $333.4K | $51.4K | - | $87.6K | $28.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.69M | $2.59M | $3.56M | - | $2.39M | $2.68M | $24.9K | - | $4.03M | $5.11M |
| SG&A | $2.08M | $2.02M | $2.44M | - | $2.27M | $2.67M | $3.12M | - | $3.34M | $3.69M |
| Total Operating Expenses | $3.78M | $4.61M | $5.99M | - | $4.66M | $5.35M | $7.14M | - | $7.37M | $8.80M |
| D&A | - | - | $140.2K | - | - | - | $123.2K | - | - | - |
| Operating Income | ($3.58M) | ($3.96M) | ($5.79M) | - | ($4.42M) | ($5.02M) | ($7.09M) | - | ($7.28M) | ($8.77M) |
| Interest Expense | - | - | $15.6K | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.54M) | ($4.48M) | ($5.74M) | - | ($4.41M) | ($5.02M) | ($7.05M) | - | ($7.27M) | ($8.75M) |
| EPS - Basic | ($0.81) | ($1.22) | ($2.40) | - | ($0.09) | ($0.14) | ($0.19) | - | ($0.34) | ($0.34) |
| EPS - Diluted | ($0.81) | ($1.22) | ($2.40) | - | ($0.09) | ($0.14) | ($0.33) | - | ($0.34) | ($0.34) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60M | $4.39M | $3.21M | $5.48M | $9.73M | $7.66M | $12.22M | $16.61M | $13.15M | $20.89M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.64M | $1.36M | $1.66M | $958.4K | $983.3K | $1.01M | $1.34M | $919.6K | $1.63M | $3.48M |
| Current Assets | $3.51M | $5.88M | $4.86M | $7.59M | $10.89M | $9.42M | $13.96M | $19.03M | $16.98M | $25.18M |
| Total Assets | $7.08M | $9.50M | $9.19M | $12.03M | $14.89M | $13.57M | $18.21M | $24.12M | $20.23M | $27.91M |
| Current Liabilities | $3.94M | $3.62M | $3.87M | $2.43M | $1.14M | $1.21M | $1.58M | $1.13M | $2.08M | $1.96M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.94M | $3.62M | $3.88M | $2.46M | $1.19M | $1.29M | $1.67M | $1.24M | $2.20M | $3.97M |
| Stockholders' Equity | $3.14M | $5.88M | $5.30M | $9.57M | $13.69M | $12.28M | $16.54M | $22.88M | $18.02M | $23.94M |
| Retained Earnings | ($132.09M) | ($128.55M) | ($124.07M) | ($118.33M) | ($113.57M) | ($109.16M) | ($104.14M) | ($97.09M) | ($89.72M) | ($82.44M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.14M) | - | - | - | ($4.37M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $901.1K | - | - | - | ($17.9K) | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1852.3% | -609.4% | -2848.8% | - | -1883.0% | -1505.6% | -13779.1% | - | -8312.5% | -31327.0% |
| EBITDA margin | - | - | -2779.9% | - | - | - | -13539.6% | - | - | - |
| Net margin | -1833.1% | -688.9% | -2821.4% | - | -1878.2% | -1506.0% | -13710.9% | - | -8305.6% | -31232.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 876.3% | 398.1% | 1749.3% | - | 1016.6% | 804.5% | 48.4% | - | 4596.6% | 18250.3% |
| SG&A / Revenue | 1076.0% | 311.4% | 1199.5% | - | 966.4% | 801.1% | 6065.1% | - | 3816.0% | 13176.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -50.1% | -47.2% | -62.4% | - | -29.6% | -37.0% | -38.7% | - | -36.0% | -31.3% |
| Return on equity | -113.0% | -76.2% | -108.1% | - | -32.2% | -40.9% | -42.6% | - | -40.4% | -36.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.89 | 1.63 | 1.26 | 3.13 | 9.54 | 7.75 | 8.85 | 16.83 | 8.18 | 12.84 |
| Quick ratio | 0.89 | 1.63 | 1.26 | 3.13 | 9.54 | 7.75 | 8.85 | 16.83 | 8.18 | 12.84 |
| Cash ratio | 0.66 | 1.21 | 0.83 | 2.26 | 8.52 | 6.31 | 7.75 | 14.69 | 6.33 | 10.65 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -370.9x | - | - | - | - | - | - | - |
| Equity multiplier | 2.26 | 1.62 | 1.73 | 1.26 | 1.09 | 1.10 | 1.10 | 1.05 | 1.12 | 1.17 |
| Liabilities / Assets | 0.56 | 0.38 | 0.42 | 0.20 | 0.08 | 0.09 | 0.09 | 0.05 | 0.11 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | 0.07 | 0.02 | - | 0.02 | 0.02 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -17.6% | 95.1% | 295.2% | - | 168.0% | 1090.4% | -23.7% | - | 75.2% | 1413.7% |
| Revenue CAGR (3y) | 57.0% | 605.7% | 103.0% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 19.0% | 21.0% | 18.3% | - | 39.3% | 42.8% | 16.0% | - | 16.1% | -71.6% |
| Net income growth (YoY) | 19.6% | 10.8% | 18.7% | - | 39.4% | 42.6% | 15.8% | - | 16.2% | -87.9% |
| EPS growth (YoY) | -800.0% | -771.4% | -627.3% | - | 73.5% | 58.8% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -77.1% | -52.1% | -67.9% | -58.2% | -24.0% | -48.7% | -47.6% | -40.9% | -62.3% | -57.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TFF Pharmaceuticals against the 5 most active filers in the same SIC group.